醋酸甲羟孕酮长效注射剂（DMPA）与癌症：世界卫生组织会议纪要
Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum from a WHO meeting.
出版信息
Bull World Health Organ. 1993;71(6):669-76.
Depot-medroxyprogesterone acetate (DMPA) is a long-acting progestational contraceptive, which is administered by injection. It was developed in the mid-1960s, when it was seen as a method that would be particularly useful for women seeking reversible contraception who had difficulty taking a pill every day. DMPA has been shown to be a highly effective contraceptive, and it has proved acceptable in a variety of settings. The drug is licensed as a contraceptive in more than 90 countries and has been widely used in a number of them, such as Thailand and New Zealand. On a worldwide basis, the licensing, acceptability, and prevalence of use have been influenced by concern that DMPA may increase the risk of cancer. Cancer of the breast has been a particular concern. This Memorandum reviews comprehensively the results of toxicological tests in animals and epidemiological studies in humans concerning the carcinogenicity of DMPA.
醋酸甲羟孕酮长效注射剂（DMPA）是一种长效孕激素避孕针，通过注射给药。它于20世纪60年代中期研发，当时被视为对寻求可逆性避孕但每天服药有困难的女性特别有用的一种方法。DMPA已被证明是一种高效的避孕方法，并且在各种环境中都被证明是可接受的。该药物在90多个国家被批准作为避孕药使用，并在其中一些国家如泰国和新西兰得到广泛应用。在全球范围内，DMPA的许可、可接受性和使用普及率受到其可能增加癌症风险这一担忧的影响。乳腺癌一直是特别令人关注的问题。本备忘录全面回顾了关于DMPA致癌性的动物毒理学试验和人体流行病学研究的结果。
Zotero 插件